Cour Pharmaceuticals

NEWS

NextGen

BioSpace’s NextGen Class of 2025 Leans Into Biopharma’s Hottest Trends

From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.

January 7, 2025

4 min read

Heather McKenzie

Pictured: Money growth/iStock, RomoloTavani

Business

Cour Raises $105M in Series A Round with Backing From Big Pharma

The investment in Illinois-based Cour Pharmaceuticals had participation from Bristol Myers Squibb, Pfizer Breakthrough Growth Initiatives and Roche Ventures.

January 31, 2024

2 min read

Tyler Patchen

IN THE PRESS

Press Releases

COUR Pharmaceuticals Secures FDA Orphan Drug Designation for CNP-104 in Primary Biliary Cholangitis

January 9, 2025

3 min read

Press Releases

COUR Pharmaceuticals Enters Collaboration and Licensing Agreement with Genentech to Develop and Commercialize Tolerogenic Therapy for the Treatment of an Autoimmune Disease

December 3, 2024

2 min read